Cargando…
Immunotherapy in Corticotroph and Lactotroph Aggressive Tumors and Carcinomas: Two Case Reports and a Review of the Literature
Once temozolomide has failed, no other treatment is recommended for pituitary carcinomas and aggressive pituitary tumors. Recently, the use of immune checkpoint inhibitors (ICIs) has raised hope, but so far, only one corticotroph carcinoma and one aggressive corticotroph tumor treated with immunothe...
Autores principales: | Duhamel, Camille, Ilie, Mirela Diana, Salle, Henri, Nassouri, Adjoa Sika, Gaillard, Stephan, Deluche, Elise, Assaker, Richard, Mortier, Laurent, Cortet, Christine, Raverot, Gérald |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563495/ https://www.ncbi.nlm.nih.gov/pubmed/32823651 http://dx.doi.org/10.3390/jpm10030088 |
Ejemplares similares
-
Aggressive corticotroph tumors and carcinomas
por: Lasolle, Hélène, et al.
Publicado: (2022) -
Sex-Related Differences in Lactotroph Tumor Aggressiveness Are Associated With a Specific Gene-Expression Signature and Genome Instability
por: Wierinckx, Anne, et al.
Publicado: (2018) -
Refractory lactotroph adenomas
por: Urwyler, Sandrine A., et al.
Publicado: (2023) -
SST5 expression and USP8 mutation in functioning and silent corticotroph pituitary tumors
por: Castellnou, Solène, et al.
Publicado: (2020) -
OR23-04 SST5 Expression and USP8 Mutation in Functioning and Silent Corticotroph Pituitary Tumors
por: castellnou, Solene, et al.
Publicado: (2020)